Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun;8(2):CNS33.
doi: 10.2217/cns-2018-0018. Epub 2019 Mar 11.

Efficacy and safety of immune checkpoint blockade for brain metastases

Maya Harary  1   2 , David A Reardon  1   3 , J Bryan Iorgulescu  1   2   4   5
Affiliations

Efficacy and safety of immune checkpoint blockade for brain metastases

Maya Harary et al. CNS Oncol. 2019 Jun.
No abstract available

Keywords: CTLA-4; PD-1; PD-L1; brain metastasis; immune checkpoint blockade; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

JB Iorgulescu is supported by an NIH 5T32HL007627-34 award. DA Reardon reports receiving speakers bureau honoraria from and is a consultant/advisory board member for Abbvie, Advantagene, Agenus, Bristol-Myers Squibb, Celldex, EMD Serono, Genentech/Roche, Inovio, Merck, Merck KGaA, Monteris, Novocure, Oncurus, Oxigene, Regeneron, Stemline and Taiho Oncology, Inc. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. - PMC - PubMed
    1. Dobry AS, Zogg CK, Hodi FS, Smith TR, Ott PA, Iorgulescu JB. Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. Cancer Immunol. Immunother. 2018;67(12):1833–1844. - PMC - PubMed
    1. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, Phase II trial. Lancet Oncol. 2012;13(5):459–465. - PubMed
    1. Di Giacomo AM, Ascierto PA, Queirolo P, et al. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 Phase II study. Ann. Oncol. 2015;26(4):798–803. - PubMed
    1. Kluger HM, Chiang V, Mahajan A, et al. Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a Phase II trial. J. Clin. Oncol. 2019;7(1):52–60. - PMC - PubMed

Publication types

MeSH terms